A real-world analysis of FDA Adverse Event Reporting System (FAERS) events for liposomal and conventional doxorubicins
Abstract The clinical application of conventional doxorubicin (CDOX) was constrained by its side effects. Liposomal doxorubicin was developed to mitigate these limitations, showing improved toxicity profiles. However, the adverse events associated with liposomal doxorubicin and CDOX have not yet bee...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2024-03-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-024-55185-4 |